1. Home
  2. PCRX vs NKX Comparison

PCRX vs NKX Comparison

Compare PCRX & NKX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • NKX
  • Stock Information
  • Founded
  • PCRX 2006
  • NKX 2002
  • Country
  • PCRX United States
  • NKX United States
  • Employees
  • PCRX N/A
  • NKX N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • NKX Finance/Investors Services
  • Sector
  • PCRX Health Care
  • NKX Finance
  • Exchange
  • PCRX Nasdaq
  • NKX Nasdaq
  • Market Cap
  • PCRX 604.7M
  • NKX 599.7M
  • IPO Year
  • PCRX 2011
  • NKX N/A
  • Fundamental
  • Price
  • PCRX $24.52
  • NKX $12.66
  • Analyst Decision
  • PCRX Buy
  • NKX
  • Analyst Count
  • PCRX 10
  • NKX 0
  • Target Price
  • PCRX $27.60
  • NKX N/A
  • AVG Volume (30 Days)
  • PCRX 741.3K
  • NKX 109.3K
  • Earning Date
  • PCRX 02-27-2025
  • NKX 01-01-0001
  • Dividend Yield
  • PCRX N/A
  • NKX 4.37%
  • EPS Growth
  • PCRX N/A
  • NKX N/A
  • EPS
  • PCRX N/A
  • NKX N/A
  • Revenue
  • PCRX $694,957,000.00
  • NKX N/A
  • Revenue This Year
  • PCRX $4.83
  • NKX N/A
  • Revenue Next Year
  • PCRX $2.16
  • NKX N/A
  • P/E Ratio
  • PCRX N/A
  • NKX N/A
  • Revenue Growth
  • PCRX 4.40
  • NKX N/A
  • 52 Week Low
  • PCRX $11.16
  • NKX $9.78
  • 52 Week High
  • PCRX $34.01
  • NKX $12.00
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 76.79
  • NKX 48.11
  • Support Level
  • PCRX $18.18
  • NKX $12.42
  • Resistance Level
  • PCRX $22.36
  • NKX $12.92
  • Average True Range (ATR)
  • PCRX 1.28
  • NKX 0.17
  • MACD
  • PCRX 0.39
  • NKX 0.01
  • Stochastic Oscillator
  • PCRX 89.19
  • NKX 48.00

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

About NKX Nuveen California AMT-Free Quality Municipal Income Fund

Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

Share on Social Networks: